| • | | | | ~ ~ | 0 3 | 6 | | | |
|---|--|--|--|---|--|--|---|--|--|
| SECU | | | | | MENTATION | PAGE | | | |
| 1a. F | | | | | 1b. RESTRICTIVE | | | | |
| Unclassi | | 4 | <u>L</u> | | - | | | | |
| 2a. SECURITY CLASSIFICATION AUTHORITY | | | | | 3. DISTRIBUTION/AVAILABILITY OF REPORT Approve for Public Release: Distribution | | | | |
| 26 DECLASSIFICATION / DOWNG 10 G SCHEDULE 1 - MAR 0.9 1992 | | | | | Unlimited | | | | |
| 4. PERFORMIN | G ORGANIZAT | ION RL | RT NUMB | ER(S) | 5. MONITORING | ORGANIZATION RE | EPORT NUMBER | R(S) | |
| - | | | | | AEOSR-TR- 92 0109 | | | | |
| 6a. NAME OF Yale Un Medicin | iversity : | ORGAN Schoo | ZATION 1 of | 6b. OFFICE SYMBOL (If applicable) | 7a NAME OF MONITORING ORGANIZATION Air Force Office of Scientific Research/NL | | | | |
| 6c. ADDRESS (| | d ZIP Co | de) | | 7b. ADDRESS (City, State, and ZIP Code) Building (10 | | | | |
| 34 Park New Hav | | 06508 | | | Building 410 Bolling AFB, D.C. 20332 | | | | |
| 8a. NAME OF ORGANIZA | | INSORIN | G | 8b. OFFICE SYMBOL (If applicable) | 9. PROCUREMENT INSTRUMENT IDENTIFICATION NUMBER | | | | |
| AFOSR | | | | NL | AF0SR-910035 | | | | |
| 8c ADDRESS (City, State, and ZIP Code) | | | | | 10. SOURCE OF FUNDING NUMBERS PROGRAM PROJECT TASK WORK UNIT | | | | |
| Building 410 Bolling AFB, D.C. 20332 | | | | | ELEMENT NO. 61102F | NO. 2312 | NO. A2 | | |
| 13a. TYPE OF Annual 16. SUPPLEME | | TION | 13b. TIME (FROM <u>10</u> | _ОVERED /1/90_то_9/30/91 | | DRT (Year, Month, I | Day) 15. PAG | | |
| 17. COSATI CODES 18. SUBJECT TERMS | | | | | Continue on revers | e if necessary and | l identify by bl | lock number) | |
| FIELD | | | | | | r Stress Amygdala Corticotropin releasing fac | | | |
| | | <u> </u> | | - 1 . | | | | | |
| anxiety. effects p directly dose-dep antagoni present o Because assay to | Previous re roduced by into the bra bendent enh ist or by les data indicate startle is m | esearc fear c in. Th ancen ions o e that t ediate e neura | h has four or stress ar is year we nent of the f the amygd the amygd d by a we al systems | dy neural systems in nd that the acoustic a re inimicked by infu- e have found that inf e acoustic startle refl gdala, a brain struct ala is part of the neu- ll-defined neural par upon which exoger | startle reflex is sion of the pept fusion of CRF i ex in rats. This are known to be aral circuitry red hway, CRF-en hous CRF acts t | senstive to bot tide corticotrop into the brain c s excitatory eff e involved in f quired for CRF hanced startle | th fear and signatures a prom auses a prom ect was block ear and stress to elevate s is a useful be behavioral ef | tress. Many factor (CRF) iounced, ked by a CRF is. The tartle. chavioral | |
| دساناNC 🖾 | FRESPONSIBLE | TED L | SAME AS | | Unclassif | | - à - | SYMBOL | |
| | Haddad | | | | 202-767-50 | | NL | JANBUL | |

DD FORM 1473, 84 MAR

83 APR edition may be used until exhausted. All other editions are obsolete.

SECURITY CLASSIFICATION OF THIS PAGE

UNCLASSIFIED

. .

_

AFOSR Technical Report Oct 1, 1990 - Sept. 1, 1991 Michael Davis Yale University




Research Objectives

The goals of the research are to study neural systems involved in the production and inhibition of fear and anxiety. Fear is a natural, adaptive response to threatening stimuli which prepares the organism to cope with the provocation. However, high levels of fear or long periods of stress can lead to abnormal, maladaptive behaviors which compromise the ability of the organism to cope with its environment. A great deal of data now indicate that the amygdala, especially the central nucleus of the amygdala, is critically involved in fear and stress. Recent evidence now strongly suggests that the peptide corticotropin releasing factor (CRF) is released within the brain in response to fear or stress. Many effects produced by fear or stress are mimicked by infusion of CRF directly into the brain and several stress-related behaviors produced by natural stimuli can be blocked by direct infusion of a CRF antagonist into the brain . A major goal of the present research will evaluate the effects of infusion of CRF into the brain on the acoustic startle reflex, a simple behavioral measure known to be sensitive to fear and stress.

Accomplishments and progress

Intraventricular (icv) infusion of corticotropin-releasing factor (CRF) (0.1 - 1.0 mg) produced a pronounced, dose-dependent enhancement of the acoustic startle reflex in rats. This excitatory effect began about 20-30 min after infusion, grew steadily over the 2-hr test period, and lasted at least 6 hrs. Higher doses of CRF (10 μ g) often produced marked facilitation and then inhibition of startle which oscillated repeatedly with a period of 10-20 min. CRF-enhanced startle did not result from an increase in sensitization produced by repetition of the startle stimulus or from a blockade of habituation. Peripheral injections of the autonomic ganglionic blockers hexamethonium (10 mg/kg) or chlorisondamine (3 mg/kg) slightly attenuated the magnitude of CRF-enhanced startle, suggesting a partial role of peripheral sympathetic activation. Intraventricular infusion of the CRF antagonist a-helical CRF9-41(ahCRF - 25 or 50 μ g) blocked CRF-enhanced startle when infused 5 min prior to CRF, indicating a central site of action. CRF-enhanced startle also was reversed when ahCRF was given 90 min after infusion of CRF. This suggests that exogenously applied CRF remains in the brain for a very long time after administration or that CRF given exogenously initiates a process that results in a long-lasting activation of endogenous CRF.

Intracisternal infusion of CRF (0.1 - 1.0 mg) increased startle with a time course and magnitude similar to that produced by icv CRF, unlike intrathecal infusion which produced a small, more rapid enhancement of startle. While lesions of the paraventricular nucleus of the



hypothalamus had no effect on icv CRF-enhanced startle, bilateral lesions of the central nucleus of the amygdala significantly attenuated the excitatory effect of icv CRF, but had no effect on intrathecal CRF-enhanced startle. Even though lesions of the amygdala blocked icv CRF-enhanced startle, local infusion of CRF into the amygdala did not significantly elevate startle. The present data indicate that the amygdala is part of the neural circuitry required for icv CRF to elevate startle, but does not appear to be the primary receptor area where CRF acts. The involvement of the amygdala in icv CRF-enhanced startle is consistent with the hypothesis that both the amygdala and CRF are critically involved in fear and stress. Because the startle reflex is elevated by both conditioned and unconditioned fear, these data lend further support to the idea that CRF infusion produces a behavioral state that resembles fear or anxiety. Because startle is mediated by a welldefined neural pathway, CRF-enhanced startle may provide a useful behavioral assay to analyze the neural systems upon which exogenous CRF acts to produce its behavioral effects.

Working conclusions and future studies:

These data indicate that the amygdala is ultimately involved in CRF enhanced startle but does not appear to be the primary site of action where icv-CRF initiates its action. Because a large number of studies have now found that icv-CRF produces a constellation of behavioral effects that resemble fear and stress, it is important to continue to determine the primary site where CRF acts after icv administration to produce these effects. If this site(s) could be found, then this would provide an anatomical anchor with which to begin to map out the neural circuitry involved in CRF induced fear and anxiety, which presumably will have relevance to a more general anatomical substrate of fear and anxiety. Using the startle reflex as a marker, further studies will evaluate the role of various anatomical structures in CRF enhanced startle. Initially, we will pick structures which a) have CRF receptors and are close to the ventricular surface and b) project to the amygdala. These will include the septal area and the bed nucleus of the stria terminalis. These areas will first be lesioned and then animals will be implanted with icv cannulas. After recovery, lesioned animals will be tested to see if icv CRF still elevates startle in these animals. If specific lesions prevent icv-CRF enhanced startle, then future studies will locally infuse CRF into these areas to see if CRF will elevate startle at lower doses and with a faster onset than that produced by icv CRF.

Because CRF markedly increases startle, it is possible that CRF may be released during a state of fear and thereby lead to an elevation of the startle reflex. We now have a great deal of data that startle is elevated by both conditioned and unconditioned fear (fear-potentiated startle). If these effects are mediated by a release of CRF, than icv or local infusion of the CRF antagonist ahCRF might block these effects, as suggested by a recent report (Swerdlow et al., 1989). Hence, a second goal of the upcoming year will be to test whether fear-potentiated startle will be blocked by icv infusion of ahCRF. Ø

. es

J

Special

Dist

DTIC COPY Articles published since the time of the prior application:

Campeau, S. and Davis, M. Reversible neural inactivation by cryogenic blockade in anesthetized and freely behaving rats. Journal of Neuroscience Methods, 1990, 32, 25-35.

Miserendino, M.J. D., Sananes, C.A., Melia, K.R., and Davis, M. NMDA antagonists in the amygdala block acquisition but not expression of conditioned fear-potentiated startle. <u>Nature</u>, 1990, 345, 716-718.

Davis, M., Mansbach, R.S., Swerdlow, N.R., Campeau, S., Braff, D.L., and Geyer, M. Apomorphine disrupts the inhibition of acoustic startle induced by weak prepulses in rats. <u>Psychopharmacology</u>., 1990, 102, 1-4.

Boulis, N.M. and Davis, M. Blockade of the spinal excitatory effect of cAMP on the startle reflex by intrathecal administration of the isoquinoline sulfonamide H-8: Comparison to the C-kinase inhibitor H-7. <u>Brain Research</u>, 1990, 525, 198-204.

Boulis, N.M., Kehne, J.H., Miserendino, M.J.D. and Davis, M. Differential blockade of early and later components of acoustic startle following intrathecal infusion of 6-cyano-7nitroquinoxaline-2,3-dione (CNQX) or DL-2-amino-5-phosphonovaleric acid (AP5). <u>Brain</u> <u>Research.</u>, 1990, 520, 240-246.

Rosen, J.B. and Davis, M. Enhancement of electrically elicited startle by amygdaloid stimulation. Physiology and Behavior, 1990, 48, 343-349.

Campeau, S., Liang, K.C., and Davis, M. Long-term retention of fear-potentiated startle following a short training session. <u>Animal Learning and Behavior</u>, 1990, 18, 462-468.

Melia, K.M. & Davis, M. Effects of septal lesions on fear-potentiated startle and the anxiolytic effects of buspirone and diazepam. <u>Physiology and Behavior</u>, 1991, 49, 603-612.

Davis, M. Animal models of anxiety based on classical conditioning: The conditioned emotional response (CER) and the fear-potentiated startle effect. In: <u>The International Encyclopedia of</u> <u>Pharmacology and Therapeutics</u>, S.E. File (Ed)., 1991, Pergamon Press, New York. 187-212.

Davis, M., Hitchcock, J.M., and Rosen, J.B. Neural mechanisms of fear conditioning measured with the acoustic startle reflex. In" <u>Neurobiology of Learning, Emotion, and Affect</u>, J. Madden IV, (Ed), 1991, Raven Press, Ltd. New York, 67-95.

Articles submitted for publication:

Rosen, J.B., Hitchcock, J.M., Sananes, C.B., Miserendino, M.J.D. and Davis, M. A direct projection from the central nucleus of the amygdala to the acoustic startle pathway: Anterograde and retrograde tracing studies. <u>Behavioral Neuroscience</u>

Hitchcock, J.M. and Davis, M. Efferent pathway of the amygdala involved in fear conditioning using the fear-potentiated startle paradigm. <u>Behavioral Neuroscience</u>

Campeau, S., Hayward, M.D., Hope, B.T., Rosen, J.B., Nestler, E.J. and Davis, M. Induction of the *c-fos* proto-oncogene in rat amygdala during unconditioned and conditioned fear. <u>Brain</u> <u>Research</u>

Liang, K.C., Melia, K.R., Miserendino, M.J.D., Falls, W. A., Campeau, S. and Davis, M. Corticotropin-Releasing Factor: Long-lasting facilitation of the acoustic startle reflex. <u>J.</u> <u>Neuroscience</u>

Liang, K.C., Melia, K.R., Campeau, S., Falls, W. A., Miserendino, M.J.D., and Davis, M. Lesions of the central nucleus of the amygdala, but not the paraventricular nucleus of the hypothalamus block the excitatory effects of corticotropin-releasing factor on the acoustic startle reflex. J. Neuroscience

Davis, M. The role of the amygdala in fear and anxiety. The Annual Review of Neuroscience

Davis, M. The role of the amygdala in conditioned fear. <u>The Amygdala: Neurobiological Aspects</u> of Emotion, Memory, and Mental Dysfunction

Professional Personnel:

Munsoo Kim, Ph.D. Post Doctoral Fellow

Serge Campeau Graduate Student

William Falls Graduate Student

Younglim Lee Graduate Student

Papers delivered relevant to this work:

1. Neural Systems Involved in Fear and Anxiety. Course in Neurobiology, Laboratory of Marine Biology, Woods Hole, Mass., June 27, 1990.

2. The Relative Roles of the Amygdala vs. the Hippocampus in Fear and Anxiety. NIMH Conference on Emotion, Mautauk Point, Long Island, New York, Sept. 22, 1990.

3. Neural Systems Involved in Fear and Anxiety. Department of Anatomy, University of Connecticut, Farminington, Ct., Oct. 10, 1990.

4. Neural Systems Involved in Fear and Anxiety. Special Invited Lecture, Society for Psychophysiology, Boston, Mass., Oct. 19, 1990.

5. Fear-potentiated startle in humans during anticipatory anxiety. With C. Grillon, R. Ameli, S.W. Woods, & K. Merikangas, Society for Neuroscience, St. Louis, MO., Oct. 29, 1990.

6. Conditioned and unconditioned effects of varying noise spectral frequencies on the acoustic startle reflex in rats. With S. Campeau, Society for Neuroscience, St. Louis, MO., Oct. 29, 1990.

7. Excitatory amino acid antagonists infused into the amygdala block extinction of fear-potentiated startle. With W.A. Falls & M.J.D. Miserendino, Society for Neuroscience, St. Louis, MO., Oct. 30, 1990.

8. Intra-amygdala injection of N-methyl-D-aspartate receptor antagonists impairs memory in an inhibitory avoidance task. With K.C. Liang, Society for Neuroscience, St. Louis, MO., Oct 30, 1990.

9. Role of excitatory amino acids in the neural circuit mediating the acoustic startle reflex. With M.J.D. Miserendino, N.M. Boulis, & R.F. Spiera, Society for Neuroscience, St. Louis, MO., Nov. 1, 1990.

10. Neural Systems Involved in Fear and Anxiety. Department of Psychology and Neuroscience, University of Pennsylvannia, Philadelphia, PA., Nov. 12, 1990.

11. The Role of the Amygdala in Stress. Department of the Navy Conference on Stress, San Francisco, Calif., Dec 1., 1990.

12. Neural Systems Involved in Fear and Anxiety. Yale Club of Utah, Salt Lake Clty, Utah, Jan. 11, 1991.

13. The Role of NMDA Receptors in the Amygdala in Conditioned Fear. Invited symposium speaker, Conference on Learning and Memory, Park City, Utah, Dec. 14, 1991.

14. Neural Systems Involved in Fear and Anxiety, Department of Psychology, University of Florida, Gainsville, Florida, March 8, 1991.

15. The Role of the Amygdala in Fear and Anxiety, Conference on Experimental Approaches to Depression and Anxiety, The Royal Institute, London, England.

16. Neural Systems Involved in Fear and Anxiety, Department of Psychology, University of Sheffield, Sheffield, England.